- Home
- LBRT vs ACAD Comparison
LBRT vs ACAD Comparison
Compare LBRT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBRT
- ACAD
- Stock Information
- Founded
- LBRT 2011
- ACAD 1993
- Country
- LBRT United States
- ACAD United States
- Employees
- LBRT N/A
- ACAD N/A
- Industry
- LBRT Oilfield Services/Equipment
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- LBRT Energy
- ACAD Health Care
- Exchange
- LBRT Nasdaq
- ACAD Nasdaq
- Market Cap
- LBRT 2.8B
- ACAD 2.6B
- IPO Year
- LBRT 2018
- ACAD 2004
- Fundamental
- Price
- LBRT $17.58
- ACAD $16.27
- Analyst Decision
- LBRT Buy
- ACAD Buy
- Analyst Count
- LBRT 9
- ACAD 19
- Target Price
- LBRT $22.56
- ACAD $26.44
- AVG Volume (30 Days)
- LBRT 2.6M
- ACAD 1.4M
- Earning Date
- LBRT 10-16-2024
- ACAD 11-06-2024
- Dividend Yield
- LBRT 1.83%
- ACAD N/A
- EPS Growth
- LBRT N/A
- ACAD N/A
- EPS
- LBRT 2.08
- ACAD 0.78
- Revenue
- LBRT $4,446,545,000.00
- ACAD $929,236,000.00
- Revenue This Year
- LBRT N/A
- ACAD $35.78
- Revenue Next Year
- LBRT N/A
- ACAD $8.58
- P/E Ratio
- LBRT $8.44
- ACAD $20.96
- Revenue Growth
- LBRT N/A
- ACAD 47.06
- 52 Week Low
- LBRT $16.57
- ACAD $14.15
- 52 Week High
- LBRT $24.75
- ACAD $32.59
- Technical
- Relative Strength Index (RSI)
- LBRT 46.56
- ACAD 51.85
- Support Level
- LBRT $16.75
- ACAD $16.37
- Resistance Level
- LBRT $18.00
- ACAD $18.71
- Average True Range (ATR)
- LBRT 0.66
- ACAD 0.73
- MACD
- LBRT 0.07
- ACAD 0.00
- Stochastic Oscillator
- LBRT 40.12
- ACAD 43.26
About LBRT Liberty Energy Inc.
Liberty Energy is an oilfield services company that provides hydraulic fracturing services—mainly pressure pumping—in major basins throughout North America. Its 2020 acquisition of Schlumberger's OneStim business segment made Liberty one of the largest pressure pumpers in North America. It also added wireline operations, two Permian frac sand mines, and an expanded technological portfolio.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.